Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1852606,
author = {Decker, Barbora and Mlčoch, Tomáš and Doležal, Tomáš and Charbonneau, Claudie and Sung, Anita H. and Vothová, Petra and Mazan, Pavol and Billová, Sabina},
booktitle = {ISPOR Europe 2018, Barcelona},
doi = {http://dx.doi.org/10.1016/j.jval.2018.09.1387},
title = {Cost-effectiveness analysis of isavuconazole for the treatment of invasive aspergillosis in the Czech Republic},
url = {https://www.valueinhealthjournal.com/article/S1098-3015(18)34689-8/fulltext},
year = {2018}
}
TY - CONF
ID - 1852606
AU - Decker, Barbora - Mlčoch, Tomáš - Doležal, Tomáš - Charbonneau, Claudie - Sung, Anita H. - Vothová, Petra - Mazan, Pavol - Billová, Sabina
PY - 2018
TI - Cost-effectiveness analysis of isavuconazole for the treatment of invasive aspergillosis in the Czech Republic
UR - https://www.valueinhealthjournal.com/article/S1098-3015(18)34689-8/fulltext
N2 - Over a lifetime horizon, isavuconazole yields additional 0.30 QALYs (7.80 vs. 7.50) at the additional total cost of €3059 (€18,664 vs. €15,605) compared with SoC, with the incremental cost-effectiveness ratio of €10,251 per QALY. PSA showed that probability of isavuconazole to be cost-effective is 75% at the WTP threshold. OWSA and SA confirmed the robustness of the base-case result while the most influential parameters were mortality and prevalence of mucormycosis.
ER -
DECKER, Barbora, Tomáš MLČOCH, Tomáš DOLEŽAL, Claudie CHARBONNEAU, Anita H. SUNG, Petra VOTHOVÁ, Pavol MAZAN a Sabina BILLOVÁ. Cost-effectiveness analysis of isavuconazole for the treatment of invasive aspergillosis in the Czech Republic. In \textit{ISPOR Europe 2018, Barcelona}. 2018. ISSN~1098-3015. Dostupné z: https://dx.doi.org/10.1016/j.jval.2018.09.1387.
|
